
Please try another search
By Manas Mishra
(Reuters) -Amgen Inc on Thursday agreed to buy ChemoCentryx (NASDAQ:CCXI) Inc for $3.7 billion to gain access to a potential blockbuster treatment for inflammatory disorders and beat quarterly revenue estimates on demand for its bone disease drug.
The deal, announced before markets opened, will also hand the company control of at least two experimental therapies for immune disorders, a field in the spotlight following AstraZeneca (NASDAQ:AZN)'s 2020 purchase of Alexion Pharmaceuticals (NASDAQ:ALXN) for $39 billion.
Amgen (NASDAQ:AMGN) has been facing stiff competition for its top-selling arthritis drug, Enbrel, from newer branded treatments and patents for the therapy are expected to expire in 2029.
Sales of Enbrel fell 8% to $1.05 billion in the second quarter.
Still, the drugmaker's revenue rose 1% to $6.59 billion, lifted by a 13% jump in sales of osteoporosis drug Prolia to $922 million. Analysts' on average had estimated revenue of $6.53 billion, according to Refinitiv data.
The company, which kept its full-year adjusted profit forecast unchanged at between $17 and $18 per share, would pay $52 in cash for each share of ChemoCentryx, a premium of nearly 116% to the target's last close.
ChemoCentryx's shares surged to trade just $1 shy of the offer price.
"We view Amgen as a logical partner to take the torch from (ChemoCentryx) and continue the launch of Tavneos," said SVB Securities analyst Joseph Schwartz.
Approved late last year to treat patients with a rare form of blood vessel inflammation or vasculitis, Tavneos brought in sales of $5.4 million in the first full quarter of its launch.
Vasculitis is caused by an over-activation of the immune system and affects about 40,000 people in the United States, according to ChemoCentryx.
Analysts expect over $1 billion in Tavneos sales by 2027, Refinitiv data shows.
By Ambar Warrick Investing.com-- Shares of Australia’s largest gold producer, Newcrest Mining Ltd (ASX:NCM), surged on Friday as it logged a higher-than-expected profit despite...
(Reuters) - Russia has failed to gain ground in cyberspace against Ukraine almost six months after its invasion of the country, the head of Britain's GCHQ intelligence service...
By David Shepardson WASHINGTON (Reuters) -General Motors Co and LG Energy Solution are considering a site in Indiana for a fourth U.S. battery cell manufacturing plant, a...
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.